Thor Trading Advisors LLC Purchases 1,083 Shares of Eli Lilly and Company $LLY

Thor Trading Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,083 shares of the company’s stock, valued at approximately $1,253,000. Eli Lilly and Company accounts for 0.4% of Thor Trading Advisors LLC’s portfolio, making the stock its 21st largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp raised its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Leerink Partners lifted their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Wells Fargo & Company increased their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a report on Friday, October 30th. HSBC raised their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Argus lifted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo met the primary endpoint in a Phase 3 trial for obstructive sleep apnea, reducing breathing interruptions by up to an average of 44%. Lilly plans to seek FDA approval for the additional use by year-end, which could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its price target to $1,700 and maintained a Buy rating, signaling continued analyst confidence in Lilly’s prospects. Jefferies price target
• Positive Sentiment: Lilly’s agreement with Hims & Hers and a similar arrangement with LifeMD expands digital access to its branded obesity medicines, including Zepbound and Foundayo. Hims’ share-price decline following its own disappointing results appears company-specific; coverage reported Lilly holding steady. Yahoo Finance article
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden, potentially permanent vision loss. The class-wide warning could raise safety concerns for patients and investors, though the condition is rare. CNBC article

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,432.60 on Wednesday. The company’s 50-day moving average price is $1,225.57 and its 200-day moving average price is $1,104.56. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.35 trillion, a P/E ratio of 46.50, a P/E/G ratio of 1.69 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 EPS. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.